Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity

Article Abstract:

A mutation in the gene for the Fas protein appears to be responsible for the Canale-Smith syndrome. This syndrome is characterized by a proliferation of white blood cells called lymphocytes and an autoimmune reaction against red blood cells and platelets. Researchers studied 4 people with the syndrome and their families. Genetic analysis revealed that all 4 had a mutation in the Fas gene, which codes for a protein that induces natural cell death. The mutation would interfere with cell death, which would lead to lymphocyte proliferation.

Author: Sullivan, Kathleen E., Elkon, Keith B., Drappa, Jorn, Vaishnaw, Akshay K., Chu, Jia-Li
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 1996
Health aspects, Immunoproliferative disorders, Cell death

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Inherited perforin and Fas mutations in a patient with autoimmune lymphoproliferative syndrome and lymphoma

Article Abstract:

A 27-year old man with the autoimmune lymphoproliferative syndrome and a large-B-cell lymphoma had heterozygous mutations in the Fas and perforin (Prf1) genes where the Fas mutation was inherited from his healthy father and the Prf1 mutation from his healthy mother. The combined effect of the two mutant genes may have contributed to the development of the autoimmune lymphoproliferative syndrome and lymphoma in this patient.

Author: Maccario, Rita, Clementi, Rita, Sabbadini, Maria Grazia, Danesino, Cesare, Dagna, Lorenzo, Rugarli, Claudio, Ferrarini, Marina, Dianzani, Umberto, Ciceri, Fabio, Bregni, Marco, Dupre, Loic, Chiocchetti, Annalisa, Locatelli, Franco
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
Case studies, Evaluation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Autoimmune lymphoproliferative syndrome with somatic Fas mutations

Article Abstract:

Six children with autoimmune lymphoproliferative syndrome (ALPS) were studied whose lymphocytes had normal sensitivity to Fas-induced apoptosis in vitro. The results reveal that somatic heterozygous mutations of Fas can cause a sporadic form of ALPS by allowing lymphoid precursors to resist the normal process of cell death.

Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2004
Science & research, Research

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Gene mutations, Gene mutation, Genetic aspects, Lymphoproliferative disorders, Autoimmune diseases
Similar abstracts:
  • Abstracts: Advances in the Treatment of Chronic Viral Hepatitis. Microchimerism: an investigative frontier in autoimmunity and transplantation
  • Abstracts: The multiple endocrine neoplasia syndromes. Therapeutic use of calcimimetics. Inherited disease involving G proteins and G protein-coupled receptors
  • Abstracts: Gut-level decisions in peace and war. Osteoclast differentiation and activation. Arming the osteoclast
  • Abstracts: Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Staphylococcus aureus protein A induces airway epithelial inflammatory responses by activating TNFR1
  • Abstracts: Advanced anterior vaginal wall prolapse is highly correlated with C. A prospective multicenter randomized trial of tension - free vaginal tape and colposuspension for primary urodynamic stress incontinence: two - Year follow - up
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.